Can We Manage Presymptomatic TTR V142I Related Risk?

Michael F. Murray; Edward J. Miller

doi:10.1016/j.jchf.2021.10.009

Can We Manage Presymptomatic TTR V142I Related Risk?

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Pages (from-to)	139-141
Number of pages	3
Journal	JACC: Heart Failure
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.jchf.2021.10.009
State	Published - Feb 2022
Externally published	Yes

Keywords

DNA-based screening
TTR V122I
TTR V142I
hs-TnI
myocardial injury
transthyretin cardiac amyloidosis

Access to Document

10.1016/j.jchf.2021.10.009

Cite this

@article{02705424600a44709d71bcde8c21df6d,

title = "Can We Manage Presymptomatic TTR V142I Related Risk?",

keywords = "DNA-based screening, TTR V122I, TTR V142I, hs-TnI, myocardial injury, transthyretin cardiac amyloidosis",

author = "Murray, {Michael F.} and Miller, {Edward J.}",

year = "2022",

month = feb,

doi = "10.1016/j.jchf.2021.10.009",

language = "English",

volume = "10",

pages = "139--141",

journal = "JACC: Heart Failure",

issn = "2213-1779",